Maven Securities’s Allogene Therapeutics ALLO Stock Holding History

Maven Securities’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,600	Closed	-$461K	–	878
2022 Q1	$461K	Sell	50,600 -47,632	-48%	-$496K	0.02%	565
2021 Q4	$1.47M	Buy	+98,232	New	+$1.73M	0.04%	255
2020 Q3	–	Sell	-200,000	Closed	-$8.56M	–	599
2020 Q2	$8.56M	Buy	+200,000	New	+$7.23M	0.59%	26

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Maven Securities's ALLO Position: Q2 2022 in Review

Maven Securities sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 50,600 shares — an estimated $461K sold.

Maven Securities first reported a position in ALLO in Q2 2020 and held it in 3 quarters. The position peaked at $8.56M in Q2 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

Maven Securities reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
Maven Securities sold 50,600 Allogene Therapeutics shares in Q2 2022, an estimated $461K.
Maven Securities first reported a position in Allogene Therapeutics in Q2 2020 and held it in 3 quarters.
Maven Securities's Allogene Therapeutics position peaked at $8.56M in Q2 2020.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Maven Securities's 13F filing for Q2 2022, filed 15 Aug 2022.